住院诊疗中闭环胰岛素输注的系统评价与荟萃分析
该系统评价与荟萃分析纳入13项住院研究(其中9项进入荟萃分析),评估闭环胰岛素输注在住院成人中的安全性、有效性与实施情况。闭环输注使目标范围内时间提高22.27%(95%CI 16.03–28.51),高血糖时间、平均血糖与血糖标准差均下降,低血糖时间、变异系数与住院时长无显著差异,未报告器械相关严重不良事件。
要点
- 闭环输注可显著提高住院患者目标范围内时间并降低高血糖时间。
- 平均血糖与血糖标准差下降,但低血糖时间与住院时长无显著改变。
- 推广需解决人员培训、技术支持与流程整合等实施障碍。
核心结论
- 闭环系统改善住院血糖控制,但对住院时长的影响与比较安全性仍不确定,广泛采用需可持续的技术与组织支持。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA指南(PROSPERO: CRD420251133486)。
- 检索EMBASE、PubMed、MEDLINE、Scopus、CINAHL与Cochrane Library,自建库至2026年8月。
- 纳入13项住院研究,其中9项进入荟萃分析;另纳入4项产时研究,其中2项进入荟萃分析。
- 采用RoB2与ROBINS-I评估偏倚风险,随机效应模型合并血糖结局与住院时长,实施数据作主题分析。
主要发现
- 目标范围内时间:合并均数差+22.27%(95%CI 16.03–28.51;p<0.001)。
- 高于范围时间:合并均数差−23.75%(95%CI −28.05至−19.45;p<0.001)。
- 平均血糖:合并均数差−1.66 mmol/L(95%CI −2.29至−1.03;p<0.001)。
- 血糖标准差:合并均数差−0.64 mmol/L(95%CI −0.85至−0.43;p<0.001);总每日胰岛素剂量更高(+10.82 IU/day,95%CI 0.02–21.62;p=0.05)。
- 低于范围时间、变异系数与住院时长无显著差异;未报告器械相关严重不良事件;产时研究显示妊娠特异性目标范围内时间提高11.82%(95%CI 5.56–18.08;p<0.001)。
关键数值与推荐
- 目标范围内时间合并均数差+22.27%(95%CI 16.03–28.51;p<0.001)。
- 高于范围时间合并均数差−23.75%(95%CI −28.05至−19.45;p<0.001)。
- 平均血糖合并均数差−1.66 mmol/L(95%CI −2.29至−1.03;p<0.001)。
- 血糖标准差合并均数差−0.64 mmol/L(95%CI −0.85至−0.43;p<0.001);总每日胰岛素剂量合并均数差+10.82 IU/day(95%CI 0.02–21.62;p=0.05)。
- 妊娠特异性目标范围内时间合并均数差+11.82%(95%CI 5.56–18.08;p<0.001)。
临床怎么用
- 住院成人使用闭环胰岛素输注可改善目标范围内时间并减少高血糖暴露。
- 应用时需关注总每日胰岛素剂量可能增加,并建立人员培训、技术支持与工作流程整合方案。
- 对住院时长与低血糖风险的改善尚不明确,需结合个体情况监测。
局限性
- 纳入研究数量有限(13项住院研究,9项进入荟萃分析)。
- 对住院时长的影响与比较安全性仍不确定。
- 实施层面存在人员培训、技术支持与流程整合等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Closed-loop (CL) insulin delivery systems have transformed outpatient diabetes care. However, evidence supporting their role in inpatient settings is limited. This systematic review and meta-analysis evaluated the safety, efficacy, and implementation of CL systems in inpatient care. Materials and Methods This review followed PRISMA guidelines (PROSPERO: CRD420251133486). Eligible studies reported glycaemic, safety, and/or implementation outcomes for adults managed with CL systems in inpatient care. EMBASE, PubMed, MEDLINE, Scopus, CINAHL, and Cochrane Library were searched from inception to August 2026. Risk of bias was assessed using RoB2 and ROBINS-I. Random-effects meta-analysis evaluated glycaemic outcomes and length of stay (LOS). Results were presented as pooled mean differences (MDs) and 95% confidence intervals (CIs). Implementation data were analysed thematically. Intrapartum outcomes were analysed separately. Results Thirteen inpatient studies were included, nine contributing to meta-analysis. CL delivery increased time in range (MD +22.27%, 95% CI: 16.03–28.51; p < 0.001) and reduced time above range (MD −23.75%, 95% CI: −28.05 to −19.45; p < 0.001), mean glucose (MD −1.66 mmol/L, 95% CI: −2.29 to −1.03; p < 0.001) and glucose standard deviation (MD −0.64 mmol/L, 95% CI: −0.85 to −0.43; p < 0.001). No significant differences were observed in time below range, coefficient of variation or LOS. Total daily insulin dose was higher (MD +10.82 IU/day, 95% CI: 0.02–21.62; p = 0.05). No serious device-attributed adverse events were reported. Implementation challenges included staff training, technical support, and workflow integration. Four additional intrapartum studies were included; two contributed to the meta-analysis, showing increased pregnancy-specific time in range (MD +11.82%, 95% CI: 5.56–18.08; p < 0.001). Conclusion CL systems improve inpatient glycaemic control, although effects on LOS and comparative safety remain uncertain. Wider adoption requires sustainable technical and organisational support.
引用
- Diabetes, Obesity and Metabolism:Closed‐Loop Insulin Delivery in Inpatient Care: A Systematic Review and Meta‐Analysis of Clinical and Implementation Outcomes
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。